文献速递主动脉疾病

类风湿关节炎患者腹主动脉瘤修复术后的结局

Outcomes of abdominal aortic aneurysm repair among patients with rheumatoid arthritis.
PubMed 文献 · J Vasc Surg · 2020-09-18

基于加拿大安大略省2003至2016年行政健康数据的回顾性队列研究,纳入14,816例65岁以上择期腹主动脉瘤修复患者,其中309例(2.0%)合并类风湿关节炎,经倾向评分匹配后比较234对患者。匹配队列平均随访4.93±3.35年,类风湿关节炎组与对照组中位生存分别为6.76年和7.31年,Cox回归显示死亡、主要不良心血管事件、再干预及二次破裂风险均无统计学显著差异。

要点

  • 择期腹主动脉瘤修复患者中类风湿关节炎患病率为2.0%。
  • 类风湿关节炎组与对照组中位生存期分别为6.76年和7.31年。
  • 死亡、主要不良心血管事件、再干预及二次破裂风险均无显著差异。

核心结论

  • 合并类风湿关节炎患者择期腹主动脉瘤修复后的生存、主要不良心血管事件、再干预及二次破裂风险与对照组无统计学显著差异。

研究设计与样本

  • 回顾性人群队列研究,使用加拿大安大略省2003至2016年关联行政健康数据。
  • 纳入14,816例65岁以上择期开放或腔内腹主动脉瘤修复患者,其中309例(2.0%)合并类风湿关节炎。
  • 经倾向评分匹配后形成234对类风湿关节炎与对照患者,匹配队列平均随访4.93±3.35年。

主要发现

  • 类风湿关节炎组与对照组中位生存期分别为6.76年和7.31年。
  • Cox回归分析显示死亡、主要不良心血管事件、再干预及二次破裂的风险均无统计学显著差异。
  • 按修复方式分层分析,上述结局风险亦无统计学显著差异。

临床怎么用

  • 对于合并类风湿关节炎的老年患者,择期腹主动脉瘤修复的围手术期决策可参考一般人群,但需进一步评估合并症及抗风湿药物对结局的影响。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the present study, we compared the outcomes of elective abdominal aortic aneurysm (AAA) repair in patients with and without rheumatoid arthritis (RA) stratified by the type of surgery. METHODS: A retrospective population-based cohort study was conducted from 2003 to 2016. Linked administrative health data from Ontario, Canada were used to identify all patients aged ≥65 years who had undergone elective open or endovascular AAA repair during the study period. Patients were identified using validated procedure and billing codes and matching using propensity scores. The primary outcome was survival. The secondary outcomes were major adverse cardiovascular events (MACE)-free survival (defined as freedom from death, myocardial infarction, and stroke), reintervention, and secondary rupture. RESULTS: Of 14,816 patients undergoing elective AAA repair, a diagnosis of RA was present for 309 (2.0%). The propensity-matched cohort included 234 pairs of RA and control patients. The matched cohort was followed up for a mean ± standard deviation of 4.93 ± 3.35 years, and the median survival was 6.76 and 7.31 years for the RA and control groups, respectively. Cox regression analysis demonstrated no statistically significant differences in the hazards for death, MACE, reintervention, or secondary rupture. Analysis of the differences in outcomes stratified by repair approach also showed no statistically significant differences in the hazards for death, MACE, reintervention, or secondary rupture. CONCLUSIONS: We found no statistically significant differences in survival, MACE, reintervention, or secondary rupture among patients with RA undergoing elective AAA repair compared with controls. Further studies are required to evaluate the impact of comorbidities and antirheumatic medications on the outcomes of elective AAA repair.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Salata K, Almaghlouth I, Hussain MA, et al. Outcomes of abdominal aortic aneurysm repair among patients with rheumatoid arthritis. J Vasc Surg. 2020. PMID: 32950628. doi:10.1016/j.jvs.2020.08.134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。